Welcome to BioMarket Group!

Analytical Tool - Prostate Cancer

Additional Information

Published Date Mar 25, 2014
Pages No
License Prices No
PDF Fact Sheet No
Format PDF & Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group

Availability: In stock

$4,650.00

Quick Overview

A unique tool for analyzing the complex competitive pressure within the field of prostate cancer.
Request free sample pages from Analytical Tool - Prostate Cancer

"Analytical Tool - Prostate Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer R&D and business development. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:


The Package Includes

  • A progress analysis on current and emerging drugs
  • Information on most companies active in prostate cancer R&D
  • Information on key industry related prostate cancer projects
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of prostate cancer therapeutics
  • Identifying emerging prostate cancer products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of prostate cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.



License Prices:

Request free sample pages from Analytical Tool - Prostate Cancer

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Lymphoma
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development. Learn More


Analytical Tool - Hematological Cancers
"Analytical Tool Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. Learn More

Other selected research from the 'Oncology' category:


Ovarian Cancer Drug Pipeline Update
BioSeeker Group have identified 357 companies plus partners who are today developing 438 drugs targeting ovarian cancer in development. across 307 different targets. In addition, there are 6 suspended drugs and another 124 drugs where development has been ceased. Learn More


B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More